Table 5.

Prior therapy, response and TTP for 13 patients with recurrent and refractory neuroblastoma

Pt. no.MYCN ampRecurrent or refractoryTumor BM, B, OPrior Cyclo/TPTPrior IRN/TMZPrior ICEPrior mAb (Y/N)Courses completeBest responseTime to best response (course)Curie score, baselineCurie score, bestTTP/censoredb (days)
2NRecurrentB, OYNNN6CR630239
11NRefractoryB, OYYYN6CR480b197
4NRecurrentBM, B, OYYNY(D)a5CR4220260
8NRecurrentBM, B, OYNYY(hu)4VGPR220b213
6NRecurrentOYNNN6PR220558
9NRecurrentBM, OYNNY(D)6PR210568
10NRecurrentBM, B, OYNNY(D)6PR260b194
13YRefractoryB, OYNNY(D)6PR240b204
1NRecurrentBM, BYYYY(hu)6SD21816274
3NRecurrentBM, BYNNY(hu)a1SD11414b81
5NRefractoryB, OYYNNa3SD277b75
7YRecurrentB, OYNNY(D)a1SD133b42
12NRefractoryBM, B, OYYNY(D)8SD22713b456
  • Abbreviations: B, bone; BM, bone marrow; CR, complete response; Cyclo, cyclophosphamide; D, dinutuximab; hu, hu14.18K322A; ICE, ifosfamide/carboplatin/etoposide; IRN, irinotecan; O, other; PR, partial response; SD, stable disease; TMZ, temozolomide; TPT, topotecan; VGPR, very good partial response.

  • aDid not complete all six courses of therapy due to: pt. 4, developed BK viral infection; pt. 3, unacceptable toxicity for thrombocytopenia >35 days; pt. 5, death related to surgery; pt. 7, allergic reaction to course 2 hu14.18K322A.

  • bTTP/censored due to: pt. 11, cis-retinoic acid following course 6; pt. 8, second malignancy; pt. 10, local consolidative radiation; pt. 13, local consolidative radiation; pt. 3, dose-limiting toxicity for thrombocytopenia >35 days; pt. 5, death related to surgery; pt. 7, allergic reaction to hu14.18K; pt. 12, mIBG therapy following course.